6245-75-6

Usage

Uses

Used in Chemical Analysis:
CDTA is utilized as a complexing agent for metal ions in chemical analysis, where its ability to form stable complexes aids in the accurate determination and measurement of metal ion concentrations.
Used in Industrial Processes:
In various industrial applications, CDTA serves as a crucial component in cleaning and etching solutions, leveraging its chelating properties to effectively remove metal ions and facilitate surface treatments.
Used in Pharmaceutical Production:
CDTA is employed in the production of pharmaceuticals, capitalizing on its metal ion binding capabilities to enhance the stability and efficacy of certain medications.
Used in Personal Care Products:
CDTA is also used in the formulation of personal care products, where it contributes to the stability and performance of these products, potentially through its interaction with metal ions present in the formulations or the environment.

InChI:InChI=1/C7H11NO6/c9-5(10)1-2-8(3-6(11)12)4-7(13)14/h1-4H2,(H,9,10)(H,11,12)(H,13,14)

Upstream product

• 79-10-7 acrylic acid 
• 142-73-4 iminodiacetic acid 
• 79-08-3 bromoacetic acid 
• 107-95-9 3-amino propanoic acid 
• 16690-93-0 sodium β-alaninate 
• 3926-62-3 sodium monochloroacetic acid 

Relevant academic research and scientific papers

Synthesis and characterization of [Mo3S4(NDABu) (HNDABu)2]3- and [Mo3S4(HNDAPr) 3]2- anions as building blocks for organic-inorganic hybrid solids

The polymetallic cation [Mo3S4(H2O) 9]4+ was used as an inorganic precursor to generate new hybrid organic-inorganic chalcogenide clusters. Three organic compounds with flexible and hanging arms were synthesized and investigated as ligands for coordination complexes with the rigid and electroactive inorganic {Mo 3S4} unit. Interestingly, the {Mo3S 4} core formed hybrid structures with the flexible H3NDABu [N-(3-carboxypropyl)iminodiacetic acid] and H3NDAPr [N-(2-carboxyethyl)iminodiacetic acid] ligands, which were characterized by X-ray crystallography. Surprisingly, no crystals were isolated, when the more rigid H3NDABn [N-(4-methoxycarbonylbenzyl)iminodiacetic acid] ligand was used. The two coordination complexes [Mo3S4(NDABu) (HNDABu)2]3- and [Mo3S4(HNDAPr) 3]2- were characterized by X-ray diffraction (XRD), IR spectroscopy, thermal gravimetric analysis (TGA), 1H NMR spectroscopy, elemental analysis, and electrochemistry. The organic ligands H3NDABu, H3NDAPr, and H3NDABn were characterized by XRD, IR, HR mass, and 13C and 1H NMR spectroscopy. [Mo3S4(NDABu)(HNDABu)2] 3- and [Mo3S4(HNDAPr)3]2- constitute promising preformed building blocks to generate new organic-inorganic hybrid molecular or extended materials. Two new promising preformed building blocks [Mo3S4(NDABu)(HNDABu) 2]3- and [Mo3S4(HNDAPr) 3]2- have been obtained. Their syntheses and characterizations are described. Copyright

Preparation of α-alaninediacetic acid or its alkali metal or ammonium salts

The invention relates to a process for preparing β-alaninediacetic acid (Ia) or its alkali metal or ammonium salts (Ib) which comprises reacting iminodiacetic acid with acrylonitrile or C1 -C4 -alkyl acrylates in weakly acid to weakly basic aqueous medium and subsequently hydrolyzing the nitrile or ester moiety to the acid or a salt. The products prepared according to the invention can be used, in particular, to form complexes.

Preparation of β-alaninediacetic acid or its alkali metal or ammonium salts

β-Alaninediacetic acid (Ia) or its alkali metal or ammonium salts (Ib) are prepared by a process in which iminodiacetic acid and acrylic acid (a) for the preparation of Ia, are reacted with one another in a nonbasic aqueous medium and (b) for the preparation of Ib, are reacted with one another in an alkaline aqueous medium or an aqueous medium containing a nitrogen base, or the Ia formed in the nonbasic medium is converted with an alkali metal base, ammonia or an amine into Ib.

Polypeptides/chelating agent nasal compositions having enhanced peptide absorption

Disclosed herein are nasal spray compositions and methods for enhancing polypeptide absorption across nasal membranes comprising a chelating agent and a polypeptide in a pharmaceutically acceptable excipient.